Physician profile
Jason Lu
NPI 1255370722
$12,778.42
in general payments reported to CMS, 2019-2025
40 companies · $3,690 in 2025
The $3,690 reported for 2025 was more than what 97% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $278 · 2020: $308 · 2021: $561 · 2022: $2,460 · 2023: $2,643 · 2024: $2,839 · 2025: $3,690.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,883 · Education: $289.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,882.58 |
| Education | $288.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $3,700.32 | 2019-2025 | Fasenra, Breztri, Tezspire |
| Glaxosmithkline, LLC. | $1,996.42 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Regeneron Healthcare Solutions, INC. | $890.32 | 2022-2025 | Dupixent |
| Jazz Pharmaceuticals INC. | $850.62 | 2023-2025 | |
| Genzyme Corporation | $842.34 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $759.76 | 2019-2025 | Ofev, Stiolto Respimat, Spiriva Respimat |
| Harmony Biosciences LLC | $555.82 | 2022-2025 | Wakix |
| Verona Pharma, INC. | $303.74 | 2025 | Ohtuvayre |
| Amgen INC. | $291.01 | 2022-2025 | Tezspire |
| Philips North America LLC | $275.49 | 2021-2025 | Vest Therapy Und, (Ak6) Vest Therapy |
| Mylan Specialty L.P. | $273.51 | 2019-2024 | Yupelri |
| Takeda Pharmaceuticals U.S.A., INC. | $224.12 | 2022-2025 | Aralast |
| Mallinckrodt Hospital Products INC. | $201.90 | 2025 | Acthar |
| Actelion Pharmaceuticals US, INC. | $183.14 | 2022-2025 | Opsumit, Uptravi |
| Ani Pharmaceuticals, INC. | $172.25 | 2023-2025 | Purified Cortrophin Gel |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insmed, INC. | $169.33 | 2022-2024 | Arikayce |
| Grifols USA, LLC | $166.05 | 2021-2025 | Prolastin-C Liquid |
| Electromed, INC. | $115.70 | 2022-2025 | Smartvest |
| United Therapeutics Corporation | $115.54 | 2023-2025 | Tyvaso, Tyvaso |
| Sanofi-Aventis U.S. LLC | $79.99 | 2022 | |
| Merck Sharp & Dohme LLC | $71.13 | 2020-2025 | Winrevair |
| Lilly USA, LLC | $56.03 | 2025 | Zepbound |
| Tactile Systems Technology INC | $53.45 | 2024 | Flexitouch Plus, Entre Plus |
| Genentech USA, INC. | $41.35 | 2022-2023 | Xolair |
| Viatris Specialty LLC | $39.20 | 2025 | Yupelri |
| Bayer Healthcare Pharmaceuticals INC. | $38.36 | 2022-2023 | |
| Baxter Healthcare | $38.01 | 2022-2023 | Hillrom - Vest System Model 105 Home Care |
| Resmed Corp | $34.24 | 2020 | |
| Pulmonx Corporation | $24.91 | 2023 | Chartis Catheter, Zephyr Endobronchial Valve, Zephyr Delivery Catheter |
| Pfizer INC. | $24.49 | 2023 | |
| Sanofi Pasteur INC. | $23.69 | 2024 | |
| Advanced Respiratory, INC | $23.13 | 2020 | |
| Sun Pharmaceutical Industries INC. | $21.08 | 2023 | Yonsa |
| Exelixis INC. | $20.87 | 2019 | |
| Phadia US INC. | $20.81 | 2024 | Immunocap |
| Inspire Medical Systems, INC. | $20.34 | 2025 | Inspire |
| Vifor Pharma, INC. | $18.04 | 2025 | Zemaira |
| Watermark Medical, INC. | $17.57 | 2024 | |
| Shire North American Group INC | $14.87 | 2019 | |
| Ambu INC. | $9.48 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Lu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.